Calcium and Aspirin Supplementation for Prevention of Preeclampsia (in High Risk Pregnancy)

/A0 个研究点目标入组 130 人开始时间: 2022年10月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Those who have one or more high-risk or two or more moderate risks of developing pre-eclampsia High risk of developing pre-eclampsia was defined as a pregnant woman with multifetal gestation, chronic hypertension, type 1 or type 2 diabetes, renal disease, autoimmune disease (e.g., systemic lupus erythematosus and antiphospholipid syndrome), and a history of pre-eclampsia. Moderate risk was defined as women with nulliparity, obesity with body mass index more than 30 kg/m2, family history of pre-eclampsia, age 35 years or older, personal history factors (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, more than 10-year pregnancy interval)

•Exclusion criteria were patients with a history of kidney or ureteric stone, parathyroid disorders, untreated nasal polyp, aspirin-induced bronchospasm, gastrointestinal or urinary hemorrhage, severe liver disease, hypercalcemia (serum corrected calcium level more than 10.5 mg/dL), allergic to aspirin or CaCO3, and other underlying diseases already receiving aspirin or calcium supplementation.

发起方